0
Selected Reports |

Regression of Recurrent Respiratory Papillomatosis With Celecoxib and Erlotinib Combination Therapy

Atikun Limsukon, MD; Irawan Susanto, MD, FCCP; Guy W. Soo Hoo, MD, FCCP; Steven M. Dubinett, MD; Raj K. Batra, MD
Author and Funding Information

Affiliations: From the Division of Pulmonary and Critical Care Medicine (Drs. Limsukon, Soo Hoo, Dubinett, and Batra), Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA; the Division of Pulmonary and Critical Care Medicine (Drs. Susanto and Dubinett), David Geffen School of Medicine at UCLA, Los Angeles, CA; and the Division of Pulmonary and Critical Care Medicine (Dr. Limsukon), Cedars-Sinai Medical Center, Los Angeles, CA.

Correspondence to: Raj K. Batra, MD, Department of Medicine, Pulmonary and Critical Care Section, Wadsworth Gene Medicine Program and the Stem Cell Institute, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Box 111Q (Pulmonary Medicine), Los Angeles, CA 90073; e-mail: rbatra@ucla.edu


Dr. Soo Hoo has received grants from Chiron, Novartis and Forest, and was involved in a conference sponsored by Cardinal Health. Dr. Dubinett serves on the scientific advisory board for Tragara Pharmaceuticals. Dr. Batra has received grants from the Department of Veterans Affairs and the National Institutes of Health, and was a site-principal investigator for Fujirebio Diagnostics, Inc. Drs. Limsukon and Susanto have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.xhtml).


© 2009 American College of Chest Physicians


Chest. 2009;136(3):924-926. doi:10.1378/chest.08-2639
Text Size: A A A
Published online

Recurrent respiratory papillomatosis (RRP) can be difficult to manage. Symptoms are related to recurrent tracheobronchial papillomas and are usually treated with bronchoscopic removal. Other modalities are added when the papilloma burden becomes too great or recurrence is too frequent, but with limited efficacy. We report a patient with progressive RRP that had become refractory to available therapy. Because papillomas overexpress epidermal growth factor receptor, along with increased expression of cyclooxygenase-2 and prostaglandin E2, it was reasoned that a combination therapy of erlotinib and celecoxib would be effective in controlling papilloma growth. After institutional approval and informed patient consent, this combination was initiated. There was a striking improvement in the number and appearance of respiratory tract papillomas, with elimination of the need for repeated papilloma removal. Pretreatment and posttreatment images document this response, and the improvement has now been maintained for nearly 2 years with effective therapy.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543